Journal of the National Cancer Institute
Papers 10000
1 page of 1,000 pages (10k results)
#1Nicolas WentzensenH-Index: 65
#2Bernd LahrmannH-Index: 14
Last. Joan L. Walker (OU: University of Oklahoma)H-Index: 61
view all 18 authors...
BACKGROUND With the advent of primary human papillomavirus testing followed by cytology for cervical cancer screening, visual interpretation of cytology slides remains the last subjective analysis step and suffers from low sensitivity and reproducibility. METHODS We developed a cloud-based whole-slide imaging platform with a deep-learning classifier for p16/Ki-67 dual-stained (DS) slides trained on biopsy-based gold standards. We compared it with conventional Pap and manual DS in 3 epidemiologic...
#1Hildur Helgadottir (Karolinska University Hospital)H-Index: 8
#2Karolin Isaksson (Lund University)H-Index: 7
Last. Håkan Olsson (Lund University)H-Index: 85
view all 8 authors...
BACKGROUND Over the past decades many regions have experienced a steady increase in the incidence of cutaneous melanoma. Here, we report on incidence trends for subsequent primary melanoma. METHODS In this nationwide population-based study, patients diagnosed with a first primary cutaneous melanoma reported to the Swedish Cancer Registry, were followed for up to ten years for a diagnosis of subsequent primary melanoma. Patients were grouped with patients diagnosed with first melanoma in the same...
#1Rachel Farber (USYD: University of Sydney)H-Index: 1
#2Nehmat Houssami (USYD: University of Sydney)H-Index: 55
Last. Katy J. L. Bell (USYD: University of Sydney)H-Index: 13
view all 8 authors...
BACKGROUND Breast screening programs replaced film mammography with digital mammography, the effects of this practice shift in population screening on health outcomes can be measured through examination of cancer detection and interval cancer rates. METHODS A systematic review and random effects meta-analysis were undertaken. Seven databases were searched for publications that compared film to digital mammography within the same population of asymptomatic women and reported cancer detection and/...
#1Otis W. Brawley (Johns Hopkins University)H-Index: 2
#2Channing J. Paller (Johns Hopkins University)H-Index: 16
#1Ben O'Leary (ICR: Institute of Cancer Research)H-Index: 8
#2Rosalind J. Cutts (ICR: Institute of Cancer Research)H-Index: 7
Last. Massimo Cristofanilli (NU: Northwestern University)H-Index: 74
view all 12 authors...
#1Janet S. de MoorH-Index: 21
#2Erin E. Kent (UNC: University of North Carolina at Chapel Hill)H-Index: 1
Last. K. Robin Yabroff (ACS: American Cancer Society)H-Index: 48
view all 10 authors...
The national prevalence of employment changes after a cancer diagnosis has not been fully documented. Cancer survivors who worked for pay at or since diagnosis (n = 1,490) were identified from the 2011, 2016 and 2017 Medical Expenditure Panel Survey and Experiences with Cancer Supplements. Analyses characterized employment changes due to cancer and identified correlates of those employment changes. Employment changes were made by 41.3% (95% CI = 38.0% to 44.6%) of cancer survivors, representing ...
#1Doris Howell (U of T: University of Toronto)H-Index: 30
#2Deborah K. Mayer (UNC: University of North Carolina at Chapel Hill)H-Index: 32
Last. Catherine M. Alfano (ACS: American Cancer Society)H-Index: 32
view all 20 authors...
Individuals with cancer and their families assume responsibility for management of cancer as an acute and chronic disease. Yet, cancer lags other chronic diseases in its provision of proactive self-management support (SMS) in routine 'everyday' care leaving this population vulnerable to worse health status, long-term disability and poorer survival. Enabling cancer patients to manage the medical, emotional consequences, and lifestyle/work changes due to cancer and treatment is essential to optimi...
#1Marco Bandini (UniSR: Vita-Salute San Raffaele University)H-Index: 21
#2J. S. Ross (State University of New York Upstate Medical University)H-Index: 78
Last. Marco Bianchi (UniSR: Vita-Salute San Raffaele University)H-Index: 87
view all 23 authors...
BACKGROUND In the PURE-01 study (NCT02736266), we aimed to evaluate the ability to predict the pathologic complete response (pT0N0) after pembrolizumab by using clinical and tumor biomarkers. METHODS In an open-label, single-arm, phase 2 study, 3 courses of 200 mg pembrolizumab preceding radical cystectomy (RC) were administered in patients with T2-4aN0M0 muscle-invasive bladder cancer (MIBC). The analyses included a comprehensive genomic profiling and programmed cell-death-ligand-1 (PD-L1) comb...
Top fields of study